IN THE CLAIMS

Please amend claims 5, 6, 9-12 and 51 as follows:

1. (PREVIOUSLY AMENDED) An isolated human inflammatory breast cancer xenograft, wherein the xenograft grows within lymphatic and blood vessel channels of an immunocompromised mouse and comprises the following properties:

i) does not express estrogen receptor and progesterone receptor; and

ii) expresses P53, EGFR, MUC1 and E-cadherin.

2. (PREVIOUSLY AMENDED) The xenograft of claim 1, wherein the level of E-cadherin expressed by the xenograft is at least two-fold greater than the level of E-cadherin expressed by a noninflammatory breast cancer xenograft.

3. (PREVIOUSLY AMENDED) The xenograft of claim 2, wherein the xenograft expresses α-catenin and β-catenin and the levels of α-catenin and β-catenin expressed by the xenograft are at least two-fold greater than the levels of α-catenin and β-catenin expressed by a noninflammatory breast cancer xenograft.

4. (PREVIOUSLY AMENDED) The xenograft of claim 3, wherein the xenograft does not express Her-2/neu.

5. (CURRENTLY AMENDED) [[An]]The isolated human inflammatory breast carcinoma xenograft of claim 1, wherein the isolated human inflammatory breast carcinoma xenograft is designated MARY-X and has~~having~~ American Type Culture Collection Accession Number PTA-2737.

6. (CURRENTLY AMENDED) An isolated in vitro culture of [[a]]the human inflammatory breast cancer xenograft of claim 1, wherein the xenograft grows as a spheroid~~and comprises the following properties:~~

~~i) does not express estrogen receptor and progesterone receptor; and~~

PAGE 5/10 * RCVD AT 5/4/2005 4:33:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:+13106418798 * DURATION (mm-ss):02-36

~~ii) expresses P53, EGFR, MUC1 and E-cadherin.~~

7. (ORIGINAL) The in vitro culture of a human inflammatory breast cancer xenograft of claim 6, wherein the spheroid can attach to a cell monolayer.

8. (ORIGINAL) The in vitro culture of a human inflammatory breast cancer xenograft of claim 7, wherein the spheroid disadheres from the cell monolayer when exposed to a culture media containing absent Ca^{++} or anti-E-cadherin antibody.

9. (CURRENTLY AMENDED) A method of generating the xenograft of claim 1 comprising the steps of:

(a) obtaining a breast sample from a patient;

(b) identifying cells in the sample as an inflammatory carcinoma exhibiting florid invasion of dermal lymphatics and which comprises the following properties:

i) do not express estrogen receptor and progesterone receptor; and

ii) express P53, EGFR, MUC1 and E-cadherin;

(c) implanting the sample into an immunocompromised mouse; and

(d) identifying the xenograft growing in the immunocompromised mouse~~host~~,

so that an isolated human inflammatory breast cancer xenograft is generated, wherein the xenograft grows within lymphatic and blood vessel channels of an immunocompromised mouse and comprises the following properties:

i) does not express estrogen receptor and progesterone receptor; and

ii) expresses P53, EGFR, MUC1 and E-cadherin.

10. (CURRENTLY AMENDED) A ~~murine~~mouse model for inflammatory breast cancer comprising an immunocompromised mouse inoculated with a human inflammatory breast cancer

PAGE 6/10 * RCVD AT 5/4/2005 4:33:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:+13106418798 * DURATION (mm-ss):02-36

xenograft, wherein the xenograft grows within lymphatic and blood vessel channels and has the following properties:

i) does not express estrogen receptor and progesterone receptor; and

ii) expresses P53, EGFR, MUC1 and E-cadherin.

11. (CURRENTLY AMENDED) The ~~animal~~mouse model according to claim 10, wherein the immunocompromised mouse is a nude mouse.

12. (CURRENTLY AMENDED) The ~~animal~~mouse model according to claim 10, wherein the human inflammatory breast cancer xenograft, is the xenograft designated MARY-X and having American Type Culture Collection Accession Number PTA-2737.

13-27. CANCELLED

28. (PREVIOUSLY PRESENTED) A method of identifying a molecule whose expression is modulated in inflammatory breast cancer comprising the steps of:

(a) providing a human inflammatory breast cancer xenograft, wherein the xenograft grows within lymphatic and blood vessel channels of an immunocompromised mouse and has the following properties:

i) does not express estrogen receptor and progesterone receptor; and

ii) expresses P53, EGFR, MUC1 and E-cadherin;

(b) determining the level of expression of at least one molecule in the human inflammatory breast cancer xenograft; and

(c) comparing the level expression of the molecule in the human inflammatory breast cancer xenograft to the level of expression of the molecule in a cell having characteristics which are distinct from the human inflammatory breast cancer xenograft,

so that a molecule whose expression is modulated in inflammatory breast cancer is identified.

PAGE 7/10 * RCVD AT 5/4/2005 4:33:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:+13106418798 * DURATION (mm-ss):02-36

29. (ORIGINAL) The method according to claim 28, wherein the level of expression of the molecule of the inflammatory breast cancer xenograft is determined by a method selected from the group consisting of: Northern Blotting, Southern Blotting, Western Blotting and polymerase chain reaction.

30-49. CANCELLED

50. (PREVIOUSLY PRESENTED) The in vitro culture of a human inflammatory breast cancer xenograft of claim 6, wherein the xenograft is the xenograft having American Type Culture Collection Accession Number PTA-2736.

51. (CURRENTLY AMENDED) The ~~non-human animal~~mouse model for inflammatory breast cancer of claim 10, wherein the xenograft is the xenograft having American Type Culture Collection Accession Number PTA-2737.

52. (PREVIOUSLY PRESENTED) The method of identifying a molecule whose expression is modulated in inflammatory breast cancer of claim 28, wherein the xenograft is the xenograft having American Type Culture Collection Accession Number PTA-2737.

PAGE 8/10 * RCVD AT 5/4/2005 4:33:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:+13106418798 * DURATION (mm-ss):02-36